Compare American Homes 4 Rent Class A (AMH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Neurocrine Biosciences Inc — how do they compare? American Homes 4 Rent Class A trades at $33.92 (market cap $12.28B), while Neurocrine Biosciences Inc trades at $152 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AMH | NBIX | |
|---|---|---|
Market Cap | $12.28B | $16.46B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $185.50 |
52-Week Low | $27.38 | $123.10 |
Enterprise Value | $17.35B | $16.48B |
Dividend Yield | 3.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
